Table 2.

Questionnaire data (mean±S.D.) before pre-single dose administration and after one-week follow up for placebo and oxytocin treatment groups

Questionnaire	Placebo Nasal Spray			Oxytocin Nasal Spray			Overall
	Pre-single dose administration	One-week Follow-Up	Mean difference	Pre-single dose administration	One-week Follow-Up	Mean difference	Partial Eta Squared	90% Confidence Interval	F (1,6)	p
Caregiver-report
AES	29.5±11.0	28.0±13.4	-1.5	27.5±12.1	25.3±15.7	-2.2	0.01	-	0.00	0.81
GDS-15	2.8±2.5	2.3±2.6	-0.5	2.5±2.9	1.8±1.7	-0.7	0.01	0.00-0.14	0.03	0.86
HBA FAQ	43.5±45.6	25.5±39.1	-18.0	28.8±39.7	0.5±1.0	-28.3	0.03	0.00-0.33	0.18	0.69
HBA SQ	12.3±8.5	8.5±5.4	-3.8	7.8±2.5	8.5±4.7	0.7	0.33	0.00-0.60	2.98	0.14
IBM	30.5±13.8	31.8±10.5	1.3	31.3±13.4	36.0±17.3	4.7	0.14	0.00-0.46	0.98	0.36
IRI-EC	17.5±3.9	18.0±5.5	-0.5	16.8±4.2	17.3±6.0	0.5	0.00	-	0.00	1.00
IRI-PT	13.8±2.8	11.5±4.7	-2.3	13.3±1.0	13.3±2.6	0.0	0.18	0.00-0.49	1.30	0.30
NPI	13.5±7.0	18.8±16.5	5.3	10.3±3.6	15.0±4.9	4.7	0.00	0.00-0.51	0.01	0.94
SDS	106.8±17.6	104.5±18.2	-2.3	100.5±30.6	95.5±23.9	-5.0	0.04	0.00-0.35	0.27	0.62
WHO-5	14.5±2.4	16.0±4.2	1.5	13.8±5.7	15.8±3.7	2.0	0.01	0.00-0.14	0.03	0.87
ZBI	40.0±12.7	41.0±15.2	1.0	41.0±13.0	38.3±13.5	-2.7	0.19	0.00-0.51	1.40	0.28
Self-report
WHO-5	19.0±4.2	19.3±2.2	0.3	18.3±4.3	20.0±3.6	1.7	0.09	0.00-0.41	0.62	0.46
GDS-15	2.3±1.3	1.8±1.0	-0.5	1.3±0.5	2.0±1.8	0.7	0.17	0.00-0.48	1.19	0.32

AES, Apathy Evaluation Scale; GDS-15, 15-item Geriatric Depression Scale; HBA FAQ, Healthy Brain Ageing Functional Assessment Questionnaire; HBA SQ, Healthy Brain Ageing Sleep Questionnaire; IBM, Intimate Bond Measure; IRI-EC/PT, Interpersonal Reactivity Index-Empathic Concern/Perspective-Taking subscales; NPI, Neuropsychiatric Inventory; SDS, Socioemotional Dysfunction Scale; WHO-5, World Health Organization (Five) Well-Being Index; ZBI, Zarit Burden Interview.